2015 News Releases

Keyword Search
2019 | 2018 | 2017 | 2016 | 2015 | 2014
Date Title
Dec 11, 2015Printer Friendly VersionNINLARO® (ixazomib) Now Available for Patients
Dec 06, 2015Printer Friendly VersionTakeda Presents Data from Phase 3 TOURMALINE-MM1 Study for NINLARO® (ixazomib), First and Only Once-Weekly Oral Proteasome Inhibitor Recently Approved for Multiple Myeloma
Dec 06, 2015Printer Friendly VersionTakeda Reports Five-Year Overall Survival Data For ADCETRIS® (Brentuximab Vedotin) Demonstrate Durable Remissions in Relapsed/Refractory Hodgkin Lymphoma
Dec 05, 2015Printer Friendly VersionMultiple Myeloma Patients and Supporters to Climb Mount Kilimanjaro to Highlight Need to Accelerate Cancer Research
Nov 20, 2015Printer Friendly VersionU.S. FDA Approves Takeda’s NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma
Nov 05, 2015Printer Friendly VersionTakeda to Present Data from Ixazomib’s Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting
Oct 27, 2015Printer Friendly VersionSeattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL)
Sep 22, 2015Printer Friendly VersionTakeda to Highlight Ixazomib Clinical Development Program at Upcoming International Myeloma Workshop
Sep 09, 2015Printer Friendly VersionU.S. FDA Grants Priority Review to Takeda’s Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Aug 21, 2015Printer Friendly VersionTakeda Announces European Medicines Agency Acceptance of Ixazomib's Marketing Authorization Application for Patients with Relapsed/Refractory Multiple Myeloma
Jul 27, 2015Printer Friendly VersionEuropean Medicines Agency Grants Accelerated Assessment of Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Jul 14, 2015Printer Friendly VersionTakeda Submits New Drug Application for Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Jun 25, 2015Printer Friendly VersionMassachusetts Takeda Employees Mobilize for 17th Annual Community Service Day
Jun 23, 2015Printer Friendly VersionTakeda Announces Presentation of New Analysis from Phase 3 AETHERA Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Hodgkin Lymphoma Patients at Risk of Relapse Following ASCT
May 12, 2015Printer Friendly VersionTakeda Announces Termination of Alisertib Phase 3 Trial in Relapsed or Refractory Peripheral T-cell Lymphoma
May 12, 2015Printer Friendly VersionTakeda Announces First Patient Enrolled in Global Phase 3 Study of Ixazomib as Maintenance Therapy for Newly Diagnosed Multiple Myeloma
May 11, 2015Printer Friendly VersionNational Cancer Center of Japan and Takeda Partner to Discover Anti-Cancer Agents
Mar 23, 2015Printer Friendly VersionTakeda Licenses Rights to Use ImmunoGen, Inc.’s Novel Antibody-Drug Conjugate Technology
Feb 17, 2015Printer Friendly VersionTakeda Announces Phase 3 MONET-A Study Evaluating Motesanib (AMG706) in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint
Feb 10, 2015Printer Friendly VersionTakeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival